Related Experiment Video For Bowel preparation
Updated: May 22, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
A randomized controlled superiority trial of 1 L (Plenvu) versus 2 L (Moviprep) polyethelene glycol plus ascorbate in
Søren Roepstorff1, Thomas Bryrup2, Morten Rasmussen3
1Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. soeren.roepstorff@regionh.dk.
Background:
Sufficient cleansing of the colonic mucosa is of great importance during colonoscopy emphasizing the need for effective preparation agents. Studies evaluating the efficacy of a novel 1 L polyethylene glycol with ascorbate (1 L-PEG-Asc), Plenvu®, versus standard 2 L polyethylene glycol with ascorbate (2 L-PEG-Asc), Moviprep®, have shown promising results regarding bowel cleansing. Nonetheless superiority of 1 L-PEG-Asc has not been shown.
Methods:
In this single-center randomized controlled superiority trial, participants of the Danish national colorectal cancer screening program scheduled for colonoscopy were randomized to either 1 L-PEG-Asc or 2 L-PEG-Asc administered as evening/morning split-dose. Primary endpoint was efficacy of the bowel preparation assessed as bowel cleansing success according to Boston Bowel Preparation Scale (BBPS), adequate defined as BBPS ≥ 2 in each segment. Secondary outcomes included excellent bowel preparation defined as BBPS = 3 in each segment, nausea, vomiting, willingness to repeat the cleansing, and lesion detection defined as polyp, adenoma, sessile serrated lesion, and cancer detection.
Results:
1275 participants were randomized to 1 L-PEG-Asc (n = 629) or 2 L-PEG-Asc (n = 646). 1 L-PEG-Asc achieved superior frequencies for adequate (92.2% vs. 86.1%, p < 0.001) and excellent preparation (59.2% vs. 43.8%, p < 0.001). Nausea (57.4% vs. 46.6%, p < 0.001) and vomiting (13.9% vs. 8.7%, p = 0.006) were more frequent in the 1 L-PEG-Asc group. Despite this, more participants were willing to repeat cleansing with this agent again (82% vs. 76%, p = 0.009). No difference was seen among lesion detection between the groups.
Conclusions:
1 L-PEG-Asc showed superior bowel cleansing efficacy, but increased rates of vomit and nausea compared to 2 L-PEG-Asc. Despite this, willingness to repeat the cleansing with the same agent was more frequent in the 1 L-PEG-Asc group.
Trial Registration:
EudraCT number: 2018-003304-39. Trial registration date 29/10 2018, study start date 17/10 2019.
Related Concept Videos
Cancer Prevention
Some...
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and solid...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Study Design: Healthy Subjects Versus Patients
Drugs for Treatment of Ulcerative Colitis in IBD
Coronary Artery Disease IV: Preventive Measures

